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Abstract 
Purpose: The administration of aromatase inhibitors is associated with bone loss in postmenopausal women. We 
assessed changes in bone mineral density (BMD) from baseline to 60 months of treatment in patients receiving anas-
trozole as initial adjuvant therapy.
Methods: Postmenopausal women with hormone receptor-positive breast cancer receiving anastrozole as adjuvant 
therapy at our center since 2004 were enrolled in this study. BMD was assessed by dual-energy X-ray absorptiometry 
at baseline and after 6, 12, 24, 36, 48 and 60 months. Oral bisphosphonate (Bis) treatment was initiated when patients 
were diagnosed with osteoporosis having a T-score of −2.5 or lower.
Results: Fifty-five patients were enrolled in the study between 2004 and 2011, and the mean follow-up period was 
53.6 months. Thirty-five patients were administered Bis (risedronate in 27 patients, alendronate in 8 patients). After 
6 months of hormone therapy, BMD decreased by 0.5% from baseline at the lumbar spine (LS) and BMD decreased 
by 1.5% at the femoral neck (FN). However, BMD increased by 1.9% at the LS and BMD decreased by 1.5% at the FN 
for 60 months of treatment. In patients treated with upfront Bis (n = 19), 5.4% BMD increase from baseline was noted 
at the LS whereas in those without Bis (n = 21) BMD decreased by 4.3% from baseline within 24 months (P < 0.0001). 
Fractures were observed in 4 patients (7.3%), and 1 patient (1.8%) had a fragility fracture.
Conclusions: Upfront treatment of Bis with anastrozole significantly increased BMD at the LS and an optimal use of 
Bis would not increase bone fractures.
Trial registration: UMIN0000017571
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Background
Aromatase inhibitors (AIs) such as anastrozole, exemes-
tane, or letrozole are currently part of the standard 
endocrine therapy in postmenopausal women with 
hormone-receptor positive early breast cancer (Gol-
dhirsh et  al. 2013; Dowsett et  al. 2009). The AIs inhibit 
the conversion of androgen to estrogen in peripheral fat 
tissues and tumor cells, which leads to a marked reduc-
tion in plasma estrogen (Geisler et al. 2008; Dixon et al. 
2008). It is reported that letrozole and anastrozole sup-
press plasma estrogen by 95.2 and 92.8% (Geisler et  al. 
2008). However, the suppression of plasma estrogen has 
been associated with an accelerated rate of bone min-
eral loss and an increased risk of bone fracture (Simp-
son and Dowsett 2002; Geisler and Lønning 2008). Not 
only the Anastrozole, Tamoxifen, Alone or in Combina-
tion (ATAC) trial (Eastell et al. 2008), but also the Breast 
International Group (BIG) 1-98 trial (Zaman et al. 2011) 
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and study of anastrozole with the bisphosphonate rise-
dronate (SABRE) trial (Van Poznak et al. 2010) show that 
AIs have been associated with bone mineral loss and an 
increase of bone fracture. Bisphosphonate (Bis) therapy 
improves bone mineral loss in patients with osteoporo-
sis (Van Poznak et al. 2010; Black et al. 1996; Harris et al. 
1999). In almost all reports of bone loss due to AIs, the 
observation period is 2  years (Van Poznak et  al. 2010; 
Lønning et al. 2005; Goss et al. 2014) and there are few 
studies of 5  years or longer (Eastell et  al. 2008; Zaman 
et  al. 2011). Only one substudy of the ATAC trial indi-
cated the changes of bone mineral density (BMD) for 
7  years (Eastell et  al. 2008). In view of the assessment 
for influence of AIs on BMD, it is important to measure 
BMD without Bis. However, adding Bis is recommended 
in daily practice for the management of AI-induced 
bone loss (Hadji et al. 2011). Osteoporotic patients were 
excluded in the bone substudy of ATAC (Eastell et  al. 
2008). Thus, we assessed changes in BMD from baseline 
to 60  months of treatment in patients receiving anas-
trozole as initial adjuvant therapy adding Bis according 
to the status of bone loss. This is the first report of the 
changes of BMD due to 5 years’ treatment of anastrozole 
for patients including osteoporosis.
Patients and methods
Patients
Postmenopausal women with hormone-receptor posi-
tive breast cancer receiving anastrozole for 5  years as 
adjuvant therapy at Tokyo Woman’s Medical University 
Medical Center East since 2004 were enrolled in this 
study. All patients had early breast cancer in stage 0–III. 
Written informed consent was obtained from all patients 
included in the study.
Treatment and assessment
All patients received anastrozole 1  mg orally every day. 
Some patients were prescribed supplementation with 
Vitamin (D 20 IU/day) and calcium (600 mg/day). BMD 
for the lumbar spine (L2–L4; LS) and femoral neck 
(FN) was assessed by dual-energy X-ray absorptiom-
etry (DEXA) at baseline and after 6, 12, 24, 36, 48 and 
60  months. Oral Bis (risedronate or alendronate) treat-
ment was initiated when patients were diagnosed as hav-
ing osteoporosis with a T-score of −2.5 or lower at the 
LS or FN according to the World Health Organization 
criteria (World Health Organization 1994). The percent-
age of changes in BMD from the baseline was calculated 
for LS and FN. We investigated the changes in BMD for 
all patients. All patients were divided into the following 
three groups: patients with upfront use of Bis, those with 
delayed use of Bis, and those without Bis. The changes 
in BMD of each group were measured. Recurrent cases 
were censored at the time of relapse in order to exclude 
the influence of other therapies (e.g. zoledronic acid or 
chemotherapy).
Statistical analysis
The Wilcoxon/Kruskal–Wallis test was used to compare 
the changes in BMD from the baseline between Bis and 
non-Bis groups. We analyzed the data of this study using 
JMP ver 10 (SAS Institute Inc., Cary, NC, USA).
Results
Fifty-five patients were enrolled in this study between 
2004 and 2011. Patients’ median age was 65 years (range 
50–85) and the mean follow-up period was 53.6 months 
(7.2–62.9).
Seven patients relapsed during the follow-up period. 
Baseline characteristics and clinicopathological factors 
are shown in Tables 1 and 2. The percentage of patients 
with osteoporosis at baseline was 41.8%, and at month 12 
it was highest (56.8%) through the entire period. The per-
centage of patients with osteoporosis gradually decreased 
in month 24 or later (Figure 1).
Overall, BMD of LS decreased by 0.5% from baseline 
and BMD of FN decreased by 1.5% at month 6 of hor-
mone therapy. However, BMD of LS increased by 1.9% 
and BMD of FN decreased 1.5% at month 60 of treatment 
(Figure 2).
Bis was administered for 34 patients (risedronate for 26 
patients, alendronate for 8 patients). Nineteen patients 
were administered anastrozole with upfront Bis at the 
same time and 15 patients had Bis added after bone 
loss (delayed Bis). In patients treated with upfront Bis 
(n  =  19), BMD of LS increased by 5.4% from baseline 
whereas in those without Bis (n =  21) BMD decreased 
by 4.3% from baseline at month 24 (P  <  0.0001). In 
patients treated with upfront Bis, BMD of LS increased 
by 2.9% from baseline whereas in those without Bis 
BMD decreased by 3.2% from baseline at month 60 
(P = 0.1182; Figure 3). Among the patients treated with 
upfront Bis, BMD of FN increased by 1.9% from baseline 
whereas in those without Bis BMD decreased by 2.7% 
from baseline at month 60 (P = 0.1741; Figure 4).
Bone fractures were observed in 4 patients (7.3%), and 
1 patient (1.8%) had a fragility fracture (Table 3). Two of 
Table 1 Baseline characteristics
No. of patients (mean ± SD) Range
Age (years) 65.2 ± 9.0 50–85
Height (cm) 153.7 ± 5.3 143–165
Body weight (kg) 55.4 ± 8.5 39–78
Body mass index (cm/kg2) 23.5 ± 3.4 17.2–32.8
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them received oral Bis. The annual bone fracture rate cal-
culated from the mean observation period (53.6 months) 
was 1.6% per year in this study.
Discussion
Anastrozole is superior to tamoxifen in terms of dis-
ease-free survival, time to recurrence, and the inci-
dence of contralateral breast cancer in postmenopausal 
woman with early breast cancer (Baum et  al. 2003). 
However, AIs are definitely associated with the reduc-
tion of BMD (Eastell et  al. 2008; Zaman et  al. 2011). 
The reduction of plasma estrogen due to AIs has been 
associated with an accelerated rate of bone mineral 
loss and an increased risk of bone fracture. However, 
there is little data on the association between changes 
of BMD and bone fractures especially for Asian 
women.
Table 2 Clinicopathological factors
Number of patients (%)
T
 Tis 2 (3.6)
 T1 27 (49.1)
 T2 23 (41.8)
 T3 0 (0)
 T4b 3 (5.5)
N
 N0 47 (85.5)
 N1–2 8 (14.5)
Estrogen receptor
 Positive 54 (98.2)
 Negative 1 (1.8)
Progesterone receptor
 Positive 38 (69.1)
 Negative 17 (30.9)
HER2
 Positive 7 (12.7)
 Negative 45 (81.8)
 Unknown 3 (5.5)
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Figure 1 Percentage of osteoporosis. Percentage of osteoporosis at 
baseline was 41.8%, the percentage at 1 year of treatment was high-
est in all patients. After that, osteoporosis decreased gradually.
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Figure 2 BMD changes in all patients. In all patients, within 6 months 
of hormone therapy, BMD decreased by 0.5% from baseline at the 
lumbar spine (solid line) and BMD decreased by 1.5% at the femoral 
neck (dot line). However, BMD increased by 1.9% at the lumbar spine 
and BMD decreased 1.5% at the femoral neck for 60 months of treat-
ment.
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Figure 3 BMD changes of lumbar spine according to upfront, 
delayed or without Bis. In patients treated with upfront Bis (bold line; 
n = 19), 5.4% BMD increase from baseline was noted at the lumbar 
spine whereas in those without Bis (thin line; n = 21) BMD decreased 
by 4.3% from baseline within 24 months (p < 0.0001).
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Figure 4 BMD changes of femoral neck according to upfront, 
delayed or without Bis. In patients treated with upfront Bis (bold line), 
1.9% BMD decrease from baseline was noted at the femoral neck 
whereas in those without Bis (dot line) BMD decreased by 2.7% from 
baseline within 60 months (p = 0.1741).
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Fractures are related to increased mortality among 
elderly patients. The mortality after hip fracture is most 
marked in the first year and thereafter tails off, but always 
exceeds the mortality of the general population (Johnell 
and Kanis 2004). Therefore, the prevention of bone loss 
is important for postmenopausal women in order to pre-
clude a fracture.
Oral Bis therapy increased BMD at clinically impor-
tant skeletal sites in postmenopausal osteoporosis, and 
decreased the incidence of bone lumbar and non-lumbar 
fractures (Harris et  al. 1999). The SABRE trial demon-
strated that the effect of Bis appeared to be manageable 
with the use of established practices for maintaining 
bone health in postmenopausal women treated with AIs 
(Van Poznak et al. 2010). MA.27B is the largest prospec-
tive bone study to assess the role of oral Bis treatment 
for women with a T-score <−2.0 with concomitant AIs 
(Goss et al. 2014). These data indicate that Bis prevented 
AI-induced bone loss in Caucasian women for at least 
two years.
Our data demonstrated that the Bis (risedronate or 
alendronate) could control BMD at the LS. However, the 
effect of Bis at the FN was restricted. In the SABRE trial, 
the effect of risedronate was demonstrated at the FN 
(Van Poznak et al. 2010). The effect of Bis at the FN was 
relatively weak in MA27B. Discordance between these 
studies is seen regarding the response to Bis at the FN. 
One reason is that the effect of Bis is essentially larger in 
LS than FN (Harris et al. 1999). Secondly, the measure-
ment error might be larger at the FN than LS. Further-
more, ethnic difference might influence the response 
to Bis at the FN. In any case, no femoral fracture was 
observed in our study. There will be no problem even if 
BMD of FN does not rise unless the incidence of femoral 
fractures increases.
Although the observation period of only two studies 
on AI and Bis in breast cancer (SABLE and MA-27B) is 
2  years (Van Poznak et  al. 2010; Baum et  al. 2003), our 
study is the result of 5  years’ observation. Our results 
showed that the BMD of the group receiving Bis at the 
LS increased during the first 4  years, and afterward 
decreased. However, the BMD after 5  years increased 
by 1.9% at the LS from baseline. Our data demonstrated 
that Bis could control BMD of LS in patients treated with 
anastrozole for 5 years. Thus, it is not necessary to exclude 
osteoporotic patients from the treatment of anastrozole.
Which is better, upfront use of Bis for the prevention 
of osteoporosis or delayed use of Bis after reduction of 
BMD? Bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) is a rare, but serious toxicity of Bis. Therefore, 
we want to avoid the use of Bis as much as possible. This 
study indicated that BMD of LS increased from baseline 
at month 60, in patients with both upfront and delayed 
use of Bis. BMD of FS increased at month 60 in those 
with upfront Bis; however, it decreased in those with 
delayed Bis. Thus, it is suggested that upfront use of Bis 
is recommended for the prevention of decreases in BMD 
of FN.
Although some data have shown that continuous treat-
ment with Bis for 5 years maintained or increased BMD 
(Black et al. 2006; Sorensen et al. 2003) in Caucasian post-
menopausal women, the BMD decreased from 4  years 
later in this study. There is a report of the BMD receiv-
ing Bis in postmenopausal Asian women. It showed that 
the pattern of the changes of BMD in Singaporean women 
was similar to that in Japanese women (Ang et al. 2011).
A review article provided some insights into the 
potential difference in osteoporosis-related phenotypes 
between Asians and Caucasians (Lei et  al. 2006). These 
phenotypic differences may partially be the result of dif-
ferent genetic backgrounds, and included the pattern of 
bone loss and response to treatment.
Bone fractures were observed in 4 patients (7.3%), and 
1 patient (1.8%) had a fragility fracture in this study. The 
annual incidence of vertebral fracture for all Japanese 
women in their 70 s was 4% per year, and 8.4% per year 
for those in their 80 s (Fujiwara et al. 2003). The annual 
bone fracture rate was 1.6% per year in this study, sug-
gesting that Bis would prevent fractures for Japanese 
women treated with AI. In the ATAC trial, bone frac-
tures were observed in 7.1% of patients over 4  years 
(Baum et al. 2003). In the BIG 1-98 trial, bone fractures 
were observed in 9.3% over 5 years (Rabaglio et al. 2009). 
In view of bone fracture, our results were similar to the 
results for Caucasians.
This is the first report on changes of BMD in more than 
50 patients treated with anastrozole for 5 years including 
osteoporotic patients receiving Bis.
Table 3 List of fracture cases
Age baseline T-score T-score in fracture Time to fracture (months) Site of fracture Cause of fracture
58 Normal Normal 6 Calcaneus Trauma
59 Normal Osteoporosis 26 Tarsal Trauma
85 Osteoporosis Osteoporosis 23 Lumber Fragility
57 Normal Normal 9 Ankle Trauma
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Conclusion
In conclusion, our study demonstrated that upfront treat-
ment of anastrozole with Bis significantly increased BMD 
at the lumbar spine, and an optimal use of Bis would not 
increase bone fractures.
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